China Reports 79,000 New COVID-19 Cases in June, 130 Severe

China recorded 79,000 new confirmed COVID-19 cases in June 2026, including 130 severe cases and one death, according to the monthly situation report published by the Chinese Center for Disease Control and Prevention on July 8. The data, which covers all 31 provinces, autonomous regions, and municipalities, reveals a significant upward trend in cases compared to previous months.

Context

The June figures represent approximately a 3.6-fold increase over May’s 21,861 cases, with severe cases rising sharply from 35 to 130 over the same period. The single death involved a patient with underlying diseases who died with COVID-19 infection, rather than from it as the primary cause. For context, January through April 2026 saw monthly case counts ranging from approximately 18,000 to 25,000, making June’s 79,000 cases a notable departure from the first four months of the year.

Since China downgraded COVID-19 from a Class A to a Class B infectious disease in January 2023, the country has managed the virus as a routinely monitored respiratory illness, with monthly reporting by the China CDC providing transparency on case numbers, variant surveillance, and hospital burden.

Key Developments

Fever clinic visits across the country rose from approximately 58,000 per day on June 1 to 65,000 per day by June 30, as reported by Sina News. Sentinel hospital surveillance showed the COVID-19 positivity rate climbing steadily from 2.9% in Week 23 (June 1-7) to 6.4% in Week 26 (June 22-28).

Variant surveillance of 3,741 sequenced cases revealed that all were Omicron sub-lineages, with NB.1.8.1 and its sub-lineages dominating at 95.9% to 98.5% of sequenced samples across the four weeks. The China CDC explicitly stated that current evidence does not suggest the emergence of new variants that may pose additional public health risk.

According to the Week 27 acute respiratory disease surveillance report published on July 9, COVID-19 ranked as the second most common respiratory pathogen detected in outpatient fever clinics at 9.6%, behind influenza at 11.6% and ahead of enterovirus at 9.1%. Among hospitalized severe acute respiratory infection cases, rhinovirus (7.1%), human metapneumovirus (5.4%), and influenza (4.5%) were the top three detected pathogens.

Analysis

The June data represents the highest monthly case count reported by China in 2026, yet the severity metrics remain reassuringly low. The case fatality rate stands at approximately 0.0013%, consistent with the Omicron-era pattern of high transmissibility but low virulence. The 130 severe cases represent just 0.16% of total confirmed cases, suggesting no change in clinical severity associated with the dominant NB.1.8.1 variant.

The increase follows a seasonal pattern observed globally, where COVID-19 has become an endemic respiratory illness with summer and winter peaks. This pattern has been consistent since 2023, with waves typically driven by waning immunity and the emergence of new Omicron sub-lineages rather than fundamentally new variants. Wenxuecity reported the data alongside reader comments noting that many mild cases likely go undetected as individuals self-treat at home without testing, suggesting the actual infection numbers may be considerably higher.

The China CDC’s public health recommendations emphasize personal protective measures — mask-wearing in crowded spaces, hand hygiene, healthy lifestyle practices, and vaccination for vulnerable populations — rather than government-mandated restrictions, reflecting the country’s current policy framework of treating COVID-19 as an endemic, manageable disease.

What’s Next

Public health authorities will continue monitoring case trends through July and August, with particular attention to whether the upward trajectory persists through the summer months. Key questions remain about regional variation in case distribution, hospital capacity in areas with higher caseloads, and the current vaccination coverage for updated boosters targeting Omicron sub-lineages. The absence of new variants of concern is a positive signal, but ongoing genomic surveillance remains critical as the virus continues to circulate.